Axoltis Pharma at SfN 2026

Nov 14–18, 2026 Washington, DC ~21k attendees Website

Axoltis Pharma brings 2 presentations to SfN 2026 in Washington. Its program at this meeting centres on ALS and the evaluation of NX210c for the disease. One thread examines NX210c’s neurovascular and peripheral effects in ALS.

Organization	SfN 2026 Attendance
AP Axoltis Pharma Lyon, France
Drug developers Develops neuroprotective therapies for neurological disorders.	Poster Sun Nov 15 1–5pm Part of Session PSTR091: ALS and Motor Neuron Diseases: Therapeutics SEALS: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Evaluating Efficacy And Safety Of NX210c In Amyotrophic Lateral Sclerosis (ALS) Patients WCC Halls A-C · Board U11 Poster Sun Nov 15 1–5pm Part of Session PSTR091: ALS and Motor Neuron Diseases: Therapeutics NX210c, an innovative peptide with neurovascular and peripheral effect in ALS WCC Halls A-C · Board U17

Organization

SfN 2026 Attendance

Axoltis Pharma

Lyon, France

Drug developers

Develops neuroprotective therapies for neurological disorders.

Poster

Sun Nov 15
1–5pm

Part of Session PSTR091: ALS and Motor Neuron Diseases: Therapeutics

SEALS: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Evaluating Efficacy And Safety Of NX210c In Amyotrophic Lateral Sclerosis (ALS) Patients

WCC Halls A-C · Board U11

Poster

Sun Nov 15
1–5pm

Part of Session PSTR091: ALS and Motor Neuron Diseases: Therapeutics

NX210c, an innovative peptide with neurovascular and peripheral effect in ALS

WCC Halls A-C · Board U17

Instantly find 20 buyers from Axoltis Pharma

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with the Society for Neuroscience. Organization details are derived from SfN’s published exhibitor list, its Neuroscience Meeting Planner and each organization’s own website. Submit a correction